Phaseline

Companies › Eurofarma Laboratorios

Eurofarma Laboratorios: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Immunology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Estradiol
Estrogen receptor alpha agonist
ESR1Phase 3Acne VulgarisFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06905210EstradiolPhase 3Acne VulgarisImmunologyFeb 2027

From the company's SEC filings

Complete response letters from FDA

Targets

ESR1 (1)

Companies with the same targets

Pfizer AstraZeneca Roche Eli Lilly Shanghai Best-Link Bioscience Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair Stemline Therapeutics Atossa Therapeutics GE Healthcare Novartis

Companies built like this

Pharvaris Netherlands AUG Therapeutics Lynk Pharmaceuticals Fujian Mindong Rejuvenation Pharmaceutical Jiangsu Genscend Biopharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.